Innopro Healthcare Ltd and Swedish Orphan Biovitrum (Sobi) have entered into an agreement for the promotion and distribution of Sobi’s products portfolio in Cyprus.
Swedish Orphan Biovitrum, based in Stockholm, Sweden, is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care. Sobi provides access to innovative treatments that transform life for people with rare diseases.
Sobi has become a leading company in haemophilia, where it seeks to shape new standards, optimise treatment, build evidence, create sustainable access and provide community support in haemophilia care.
The Sobi Organisation spans more than 30 countries, delivering treatments to patients in over 70 countries across the globe.